Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron Pharmaceuticals

The FDA has accepted for review the supplemental marketing application seeking approval for Dupixent (dupilumab). It is an add-on treatment for children aged 6 to 11 years with uncontrolled moderate-to-severe asthma, jointly developed by Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) under a global collaboration agreement.

Sanofi/Regneron's Dupixent Application For Asthma In Children Accepted For FDA Review

AbbVie

Algonquin Power & Utilities

British American Tobacco

Cardinal Health

Canadian Natural Resources

Chevron

Enbridge

Novartis

Pembina Pipeline

People's United Financial

AT&T

TC Energy

Unilever

Kiplinger "insights for investors" online first offered this list of 91 "Top Dividend Stocks From Around The World" 7/13/20. Data updated 3/1/21 flagged 14 with yields ripe with future upside.

The 91 Kiplinger 'Top Dividend Stocks On Earth' March Update

Sanofi's Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members

Sanofi (SNY) Presents at Cowen 41st Annual Healthcare Conference (Transcript)

Sanofi's experimental COVID-19 was delayed in December, but they plan to apply for the regulatory submission in the H2 of 2021.

Sanofi Still Looks Promising Despite The COVID-19 Vaccine Delay

STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that it is entering into a joint Phase II clinical study to treat patients with multiple myeloma using XNK's leading drug candidate in combination with Sanofi's anti-CD38 antibody Sarclisa (isatuximab)....

XNK Therapeutics partners with Karolinska Institutet on Phase II study in patients with multiple myeloma with support from Sanofi

Biogen

GlaxoSmithKline

Imperial Brands PLC

Kellogg

Lockheed Martin

Masco

Merck

Roche Holding AG

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating).

Wide-Moat Stocks On Sale - The March 2021 Heat Map

Health Canada has approved Sanofi's SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) DUPIXENT (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis in children aged six to 11 years whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT is also approved in Canada to treat adult patients with severe chronic rhinosinusitis with nasal polyposis and for the treatment of severe asthma in patients 12 years and older.

Sanofi/Regeneron's DUPIXENT Wins Canada Approval For Atopic Dermatitis In Children Aged 6-11

MUNICH--(BUSINESS WIRE)-- #AAV--SIRION Biotech announced that it signed a license and collaboration agreement with Sanofi.

SIRION Biotech Announces Collaboration with Sanofi to Innovate Gene Therapy Treatments with Improved Adeno-Associated Virus Capsids

The FDA approved expanded use of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi's SA (NASDAQ: SNY) immunotherapy Libtayo (cemiplimab-rwlc) as monotherapy in newly diagnosed advanced lung cancer, marking the third approval for Libtayo and second this month. The drug is now cleared for adults with non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression of at least 50%, a protein that's correlated with response to immunotherapy, and have metastatic or locally advanced tumors that can't be removed by surgery and must not have EGFR, ALK or ROS1 aberrations.

FDA Approves Regeneron/Sanofi's Libtayo For Front-Line Lung Cancer

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi: Information concerning the total number of voting rights and shares - January 2021

Sanofi and GlaxoSmithKline PLC (LON:GSK) have announced details of a phase II study for their collaborative coronavirus vaccine. Britain's Glaxo and France's Sanofi are the world's two largest vaccine companies but have been left floundering in their attempts to come up with a product by rivals Pfizer/BioNTech, AstraZeneca/Oxford University and Moderna.

GlaxoSmithKline and Sanofi to push ahead with phase II trial of Covid-19 vaccine

The drugmakers pushed back the rollout of their experimental COVID-19 shot in December because a study found it generated an "insufficient" immune response to the virus in people older than 50 years.

Sanofi, GlaxoSmithKline start new COVID-19 vaccine study after failed trial

Sanofi SA (NASDAQ: SNY)and GlaxoSmithKline Plc (NYSE: GSK) have initiated a new Phase 2 study with 720 volunteers aged 18 and finalize the antigen dosage for Phase 3 evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate. The companies have corrected the shot's formulation, which was weaker and failed to create enough immune response in people 50 years and older.

Sanofi/GlaxoSmithKline Initiate COVID-19 Vaccine Development After Setback

Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Bristol-Myers

Bristol-Myers Squibb Co (NYSE: BMY) and Sanofi SA (NASDAQ: SNY) were ordered to pay the state of Hawaii more than $834 million for illegally marketing their blood-thinning drug Plavix, Bloomberg reports. Hawaii Attorney General Clare Connors' lawyers showed the companies didn't adequately disclose the blood thinner was ineffective for as many as 30% of users in the state, the judge said.

Bristol-Myers, Sanofi Fined $834M In Hawaii Over Plavix: Bloomberg

A judge in Hawaii on Monday ordered Bristol-Myers Squibb Co and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from its blood thinner Plavix.

Bristol-Myers, Sanofi ordered to pay Hawaii $834 million over Plavix warning label

A COVID-19 vaccine candidate developed by Sanofi and U.S. group Translate Bio "will not be ready this year," the French drugmaker's chief executive told Le Journal du Dimanche newspaper.

Sanofi's mRNA COVID-19 vaccine candidate not ready this year, CEO says

Growth of revenues and profitability have returned, with impressive leaps in cash generation. A true dividend aristocrat with 27 years of dividend increases.

Sanofi: Revival Of Fortunes

Sanofi SA (NASDAQ: SNY) has launched a takeover offer for Kiadis Pharma NV (OTC: KIADF) to represent an aggregate adjusted equity value of €308 million. The takeover offer is priced at €5.45 per share in cash.

Sanofi Offers Cash Buyout For Kiadis

This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 4 paragraph 1, Article 10 paragraph 1 and 3, and Article 18 paragraph 3 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft, the “Decree”) in connection with the intended public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer”). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the offer memorandum dated 10 February 2021 (the “Offer Memorandum”), approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten, the “AFM”) on 10 February 2021 and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten) on [11 February 2021], and which is available as of today. This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, any jurisdiction in which such release, publication or distribution would be unlawful.

Sanofi launches recommended cash offer for all shares in Kiadis

The FDA approves Sanofi (SNY)/Regeneron's Libtayo for treating patients with advanced/metastatic basal cell carcinoma. The is the second approved indication for the drug in the United States.

Sanofi (SNY)/Regeneron's Libtayo Gets FDA Nod for 2nd Indication

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) immunotherapy Libtayo (cemiplimab-rwlc) has scored approval from the FDA for the treatment of advanced basal cell carcinoma (BCC), the most common type of skin cancer in the U.S. The FDA has indicated Libtayo for treating previously-treated, advanced BCC patients who have already received a hedgehog pathway inhibitor (HHI) or who cannot be treated with an HHI.

Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer

Sanofi (SNY) CEO Paul Hudson on Q4 2020 Results & Capital Markets Day (Transcript)

Sanofi's (SNY) Q4 earnings and sales miss estimates. Dupixent drives sales growth in the quarter

News for Sanofi Stock (SNY)